Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
about
Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, FranceTwo years after pandemic influenza A/2009/H1N1: what have we learned?Seroprevalence to influenza A(H1N1) 2009 virus--where are we?Pre-existing cross-reactive antibodies to avian influenza H5N1 and 2009 pandemic H1N1 in US military personnelHemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infectionSafety and immunogenicity of influenza A H1N1 vaccines.A lower than expected adult Victorian community attack rate for pandemic (H1N1) 2009.Highly conserved cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses.Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, IndiaInfluenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter.Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong.Study on age-dependent pre-existing 2009 pandemic influenza virus T and B cell responses from Chinese populationSerological analysis of human pandemic influenza (H1N1) in Thailand.Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai populationComparison of pandemic (H1N1) 2009 and seasonal influenza viral loads, Singapore.Sus scrofa miR-204 and miR-4331 Negatively Regulate Swine H1N1/2009 Influenza A Virus Replication by Targeting Viral HA and NS, Respectively.Swine influenza virus antibodies in humans, western Europe, 2009.Did modeling overestimate the transmission potential of pandemic (H1N1-2009)? Sample size estimation for post-epidemic seroepidemiological studiesSensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations.The seroprevalence of pandemic influenza H1N1 (2009) virus in China.Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.Serological survey of antibodies to influenza A viruses in a group of people without a history of influenza vaccination.The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccinationDifferential effects of pandemic (H1N1) 2009 on remote and indigenous groups, Northern Territory, Australia, 2009.Seroprevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan.Perinatal outcomes and congenital abnormalities in the newborns of women affected by the 2009 pandemic influenza A (H1N1) in Beijing, China.Cumulative incidence of pandemic influenza A (H1N1) 2009 by a community-based serological cohort study in Selenghe Province, MongoliaWhy was the 2009 influenza pandemic in England so small?Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting.Titering of 2009 pandemic H1N1 influenza virus hemagglutinin inhibition antibody in nonvaccinated pregnant women in Shiraz, Southern Iran.Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus.Temporal trends of influenza A (H1N1) virus seroprevalence following 2009 pandemic wave in Guangdong, China: three cross-sectional serology surveys.Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos.Low Level of Cross-Reactive Antibodies to Pandemic Influenza (H1N1) 2009 Virus in Humans in Pre-Pandemic Period in Maharashtra, India.The 2009 pandemic (H1N1) viruses isolated from pigs show enhanced pathogenicity in mice.Seroprevalence of antibodies to influenza A/H1N1/2009 among transmission risk groups after the second wave in Mexico, by a virus-free ELISA method.Reliability of pseudotyped influenza viral particles in neutralizing antibody detectionIntracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation
P2860
Q28730980-E08C0D26-9743-4D45-A059-8B6DE7D6F220Q30224656-3116F723-7300-4433-9A36-677F46B79155Q30226546-AF54ED0C-77F1-4FE2-9108-0C1682189BBBQ30356053-CD3FE8FA-506A-4069-A811-A03FC61D8D25Q30366832-47C22025-E70E-45EA-8D92-E6A2A0733565Q30387728-1819BA23-1702-4524-AD3C-26A9D7625DBCQ30391237-0A2BECF2-51C1-4AE5-95AC-4D38C6851B58Q30392701-4EAF49A0-A69E-4467-98DD-8DC68B953EDCQ30392935-D8325E0D-E0DA-4B38-9E68-D13533DFFB39Q30393480-B58A4DC5-DBC7-416D-8B5E-5BE0BC6EE7DEQ30394136-7797EA3F-9964-4B26-B1A8-C2CBAB8C2F7FQ30398477-83ADADE0-9222-4D1D-9ADC-EE9A0F173216Q30398905-38563E93-B1FA-491E-93BC-8D567986344AQ30399164-0F81E6C1-9ED5-484A-B685-9072B3A5A1F9Q30399323-182E88A3-084A-4D60-A8B8-3FAA574D131FQ30400612-D331CEE0-E915-4A6E-9C2A-AC8E549F16F1Q30400617-44BB5D49-21B8-4901-8E81-61D0AE8B9D6BQ30401351-387DF8A3-0940-4541-BC97-54BC805D3EC7Q30401611-7E1A9968-D90E-4EC3-98E7-2241257E47D3Q30402225-E6023706-A03A-43BD-84A6-15498A3B71BFQ30404358-AE478555-AEE8-477F-B219-85C308EC1963Q30404694-579F9ABE-20EE-4F37-BBFE-2E3CE8946DD2Q30406109-3E3B5165-F0D8-4989-B686-1D7AB6307E22Q30406690-166D4200-D340-408B-BF44-81AD5E5C3AD4Q30406971-F956615B-002A-46B3-B471-A391FD8CE001Q30409603-8328CBAA-6E2E-4FF4-9975-E7AA5866DDC8Q30413007-1D6908A0-EB3D-4314-ACE2-94C647D32306Q30413269-85FFB633-9E7A-4748-9CCC-7E8C29F17547Q30416214-3E8D6F38-3A9F-4087-B4DB-B55191755D58Q30417281-ECDADD12-9A32-4324-AE9F-33B8D1E5678FQ30417675-AB1BC1BC-DDE6-4D2A-80A8-259D67DCB2FEQ30418331-A8E6F234-4290-4367-9723-6CBBC8175BBEQ30423319-ABBC52CA-4D37-4A48-A0DB-4CD7DADB9232Q30428692-C0A91CC5-00D1-4EB0-A5D0-0D5929814C6CQ30430052-07A95CC9-2CE0-4B69-ABF6-3F7A86A09FEFQ30431398-D2EB2837-844A-4325-8F3B-B05255DB33E9Q30431808-C3537140-7AD0-460D-A820-089E4294C3D7Q33698250-936ECD6D-54C8-4F8B-8076-84F8E1137302Q34600142-7254FBDA-F8DE-4E5C-9403-79AAECCDE54EQ35037006-8769B0F4-5DDE-45F2-81BA-62867D411A86
P2860
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@ast
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@en
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@nl
type
label
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@ast
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@en
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@nl
prefLabel
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@ast
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@en
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@nl
P2093
P2860
P50
P356
P1476
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China
@en
P2093
Baiqing Dong
Menno D de Jong
Xiaohui Fan
P2860
P304
P356
10.3201/EID1511.090868
P407
P577
2009-11-01T00:00:00Z